Devonian Health Group, Inc. · TSXV:GSD
Devonian Health — Shareholder Meeting (February 2024)
27 slides from Devonian Health's shareholder meeting presentation, Feb 20, 2024
Slide 1: Welcome – Bienvenue: Annual General Meeting of Shareholders
Welcome – Bienvenue Annual General Meeting of Shareholders February 20, 2024 TSVx : GSD OTCQB : DVHGF
Slide 2: Cautionary Statements
Cautionary Statements Certain statements contained in this document constitute forward-looking information and forward-looking statements (collectively, “forward-looking statements”) pursuant to the Applicable Securities Regulations. All statements, other than statements of historical fact, containe
Slide 3: Company Overview
Company February 2024 Overview Farm toPharm™ TSXv : GSD / OTCQB : DVHGF 3
Slide 4: Devonian Health Group Snapshot
Devonian Health Group Snapshot A Leader in the Discovery, Research & Top product candidate: Thykamine Development (R&D) of Botanical Drugs/ • Novel multi-application anti-inflammatory Pharmaceuticals (prescriptions) following US-FDA, Germany-BfArM, and Health • First- Pediatric Atopic Dermatitis (Ec
Slide 5: Experienced Leadership
Experienced Leadership Luc Gregoire CPA, CA Colette Laurin CPA, CA Dr André P. Boulet, PhD Pierre Montanaro Dr. Daniel Bouthillier, PhD President & CEO CFO Chief Scientific Officer President, VP Research Altius Healthcare Inc. Sipar, LP Farm toPharm™ TSXv : GSD / OTCQB : DVHGF 5
Slide 6: Board of Directors
Board of Directors Executives with extensive Pharma and Public Company Experience David Baker André Boulet Ed Dahl Jean Forcione Luc Gregoire Louis Flamand PHD Chairman Founder & CSO President & CEO Sipar, LP Farm toPharm™ TSXv : GSD / OTCQB : DVHGF 6
Slide 7: State-of-the-Art Pharmaceutical Grade (cGMP) Extraction Facility
State-of-the-Art Pharmaceutical Grade (cGMP) Extraction Facility PROCESSING FACILITY • 1,625 square meters • Located in Montmagny (Québec) • Water system upgradable to produce injectables / sterile eye solutions PHARMACEUTICAL GRADE • Full scale facility with custom designed equipment • Full traceab
Slide 8: Intellectual Property Portfolio
Intellectual Property Portfolio U.S. and international patent estate Devonian has seven (7) issued patents and one (1) pending patent application across several geographical areas such as Canada, US, Europe and Japan, covering: ▪ Extraction process (in the absence of the ability to extract plant ing
Slide 9: The Life Science Industry Opportunity
The Life Science Industry Opportunity A. US $2.07 TRILLION1 ▪ The projected revenue of Global Pharmaceutical market by 2028. B. USA and Canada Market Share2,3 ▪ Nearly half of it comes from U.S. (45%) and Canada (2%). C. High Net Profit Margin industry 21.6 %4 D. Patent Cliff Challenge US $200 BILLI
Slide 10: Pipeline in a Product
Pipeline In A Product Potential to study Thykamine : Corporate Focus on Dermatological inflammatory disorders • Atopic Dermatitis ➢ Adult ➢ Pediatric • Protection from • Hand & Foot Syndrome associated to Chemotherapy • Radiodermatitis associated to Radiotherapy Farm toPharm™ TSXv : GSD / OTCQB : DV
Slide 11: Thykamine: Atopic Dermatitis
THYKAMINE : ATOPIC DERMATITIS #1 FOCUS Farm toPharm™ 11
Slide 12: Atopic Dermatitis Phase 2 Trial - Adult Patient Population
1 Atopic Dermatitis (AD) Phase 2 Trial - Adult Patient Population Setting Stage for Phase 3: Strong clinical results reflecting safety and efficacy forming the basis of future development efforts in dermatology Proportion of patients achieving Primary Endpoint : IGA 0 or 1 AND 2-point Reduction from
Slide 13: Atopic Dermatitis Phase 2 Trial - Safety = Placebo
1 Atopic Dermatitis (AD) Phase 2 Trial - Adult Patient Population- Safety = Placebo Incidence of AEs, n (%) that were probably, possibly, or definitely related to study medication (safety population). Thykamine Thykamine Thykamine (PUR 0110) (PUR 0110) (PUR 0110) Severity Adverse event Vehicle (n=40
Slide 14: Thykamine Pediatric Development Program
Thykamine Pediatric Development Program Farm toPharm™ 14
Slide 15: Global Atopic Dermatitis Market Summary
Global Atopic Dermatitis Market Summary Market value (US $ Bn) Global AD Market $ 25.3 Bn AD Drug Treatment Market $ 19.7 Bn AD Topical Drug Market $ 13.3 Bn AD Mild-to-Moderate Market (80.8% of Topical) $ 10.8 Bn AD Pediatric Market (62.4%) $ 6.7 Bn Farm toPharm™ 15
Slide 16: Why should we focus on Pediatric Segment?
Why should we focus on Pediatric Segment? ▪ High value, but not a crowded market ▪ Most treatments available can only be used on alternate basis – none can be used on a continuous basis ▪ Younger patients (<12 years): underserved within this market – Parents’ safety and tolerability concerns ▪ Leade
Slide 17: Pediatric Mild-to-Moderate Atopic Dermatitis Treatment Landscape
Pediatric Mild-to-Moderate Atopic Dermatitis Treatment Landscape ▪ Topical Corticosteroids ▪ Tacrolimus 0.03% ▪ Fear and anxiety regarding treatment with topical ▪ Calcineurin inhibitor. corticosteroids ▪ Use in pediatric ≥2 years. ▪ Topical steroid withdrawal reactions ▪ Concerns regarding its immu
Slide 18: 2023 Year in Review
2023 Year in Review Farm toPharm™ TSXv : GSD / OTCQB : DVHGF 18
Slide 19: 2022/23 Corporate Milestones
2022/23 Corporate Milestones ▪ Leadership transformation and expertise ▪ R&D, pharmaceutical industry and capital markets ▪ Publicizing of Phase 2 Atopic Dermatitis- Adult Clinical Study ▪ Journal of Drugs in Dermatology, Oct 2022 ▪ Presentation at the 6th Dermatology Drug Development Summit, Nov 20
Slide 20: 2022/23 R&D Milestones
2022/23 R&D Milestones ▪ Published in International Journal of Non-Communicable Diseases: ▪ “Coronavirus disease 2019: The prospect for botanical drugs’ polymolecular approach” ▪ Finalized protocol for pediatric Atopic Dermatitis clinical study ▪ Start Phase 2/3 pediatric study once capital raised ▪
Slide 21: 2022/23 R&D Milestones
2022/23 R&D Milestones ▪ Developed new serum formulation with R-Spinasome® ready to be used within the anti-ageing Purgenesis brand ▪ Developed two new regenerating creams with two different concentrations aimed at Professionals and Consumers: ▪ Lower concentration for Consumers ▪ Higher concentrati
Slide 22: Devonian - Supply-chain disruptions
Devonian - Supply-chain disruptions ▪ Manufacture of pharmaceutical creams for clinical studies ▪ Contract manufacturers are overwhelmed ▪ It took over 9 months to find and conclude an agreement with a manufacturer (Cambrex) ▪ The selected manufacturer highlighted supply chain disruptions ▪ Lead tim
Slide 23: 2022/23 Altius Healthcare Inc.
2022/23 Altius Healthcare Inc. ▪ Pantoprazole supply resumed ▪ Resumed sales growth ▪ Prepared for new product launch ▪ Authorized generic version of a major GI tract remedy ▪ Launched in Q2/2024 Farm toPharm™ TSXv : GSD / OTCQB : DVHGF 23
Slide 24: 2024 Growth Phase
2024 Growth Phase Farm toPharm™ TSXv : GSD / OTCQB : DVHGF 24
Slide 25: 2023/24 Corporate Milestones
2023/24 Corporate Milestones ▪ Pursue several vectors to obtain required funding. ▪ Capital markets, financial structure ▪ Shareholder motions today has improved our alternatives/access ▪ Build up Business development function: ▪ Development and commercialization partner ▪ Altius additional in-licen
Slide 26: 2023/24 R&D Milestones
2023/24 R&D Milestones ▪ Focus efforts on Phase 2/3 clinical trial for pediatric Atopic Dermatitis ▪ Finalize Cell-Based Assay for Thykamine QA/QP process in Q3/2024 ▪ Regulatory qualification of production ▪ Prepare future studies to follow AD ▪ Pivotal study in radiodermatitis ▪ Phase 2 clinical s
Slide 27: Thank you ! Merci !
Thank you ! Merci ! https://groupedevonian.com/ 360 Des Entrepreneurs, Montmagny, Quebec, Canada G5V 4T1 TSXv : GSD OTCQB: DVHGF
Devonian Health Group — Shareholder Meeting (February 2024) on 6ix